DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of the Application
The amendment and election of 21 August 2026 are entered.
Claims 1-34 are pending. Claims 18-32 are withdrawn without traverse. Claims 1-17, 33, and 34 are being examined on the merits.
Election/Restrictions
Applicant’s election of Group I (claims 1-17, 33, and 34) and SEQ ID NO: 196 in the reply filed on 21 August 2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)).
Claims 18-32 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 21 August 2026.
A search of SEQ ID NO: 196 indicates it is free of the prior art. The search was extended to other members of the genus.
Drawings
The drawings are objected to because Figure 1 fails to comply with sequence disclosure requirements as discussed below. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.
Nucleotide and/or Amino Acid Sequence Disclosures
Summary of Requirements for Patent Applications Filed On Or After July 1, 2022, That Have Sequence Disclosures
37 CFR 1.831(a) requires that patent applications which contain disclosures of nucleotide and/or amino acid sequences that fall within the definitions of 37 CFR 1.831(b) must contain a “Sequence Listing XML”, as a separate part of the disclosure, which presents the nucleotide and/or amino acid sequences and associated information using the symbols and format in accordance with the requirements of 37 CFR 1.831-1.835. This “Sequence Listing XML” part of the disclosure may be submitted:
1. In accordance with 37 CFR 1.831(a) using the symbols and format requirements of 37 CFR 1.832 through 1.834 via the USPTO patent electronic filing system (see Section I.1 of the Legal Framework for Patent Electronic System (https://www.uspto.gov/PatentLegalFramework), hereinafter “Legal Framework”) in XML format, together with an incorporation by reference statement of the material in the XML file in a separate paragraph of the specification (an incorporation by reference paragraph) as required by 37 CFR 1.835(a)(2) or 1.835(b)(2) identifying:
a. the name of the XML file
b. the date of creation; and
c. the size of the XML file in bytes; or
2. In accordance with 37 CFR 1.831(a) using the symbols and format requirements of 37 CFR 1.832 through 1.834 on read-only optical disc(s) as permitted by 37 CFR 1.52(e)(1)(ii), labeled according to 37 CFR 1.52(e)(5), with an incorporation by reference statement of the material in the XML format according to 37 CFR 1.52(e)(8) and 37 CFR 1.835(a)(2) or 1.835(b)(2) in a separate paragraph of the specification identifying:
a. the name of the XML file;
b. the date of creation; and
c. the size of the XML file in bytes.
SPECIFIC DEFICIENCIES AND THE REQUIRED RESPONSE TO THIS NOTICE ARE AS FOLLOWS:
Specific deficiency - Sequences appearing in the drawings are not identified by sequence identifiers in accordance with 37 CFR 1.831(c). Sequence identifiers for sequences (i.e., “SEQ ID NO:X” or the like) must appear either in the drawings or in the Brief Description of the Drawings.
Required response – Applicant must provide:
Amended drawings in accordance with 37 CFR 1.121(d) inserting the required sequence identifiers;
AND/OR
A substitute specification in compliance with 37 CFR 1.52, 1.121(b)(3), and 1.125 inserting the required sequence identifiers (i.e., “SEQ ID NO:X” or the like) into the Brief Description of the Drawings, consisting of:
• A copy of the previously-submitted specification, with deletions shown with strikethrough or brackets and insertions shown with underlining (marked-up version);
• A copy of the amended specification without markings (clean version); and
• A statement that the substitute specification contains no new matter.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 1, 3-7, 10-17, 33, and 34 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for a method of systemically delivering a sulfated mini nucleosome core protein to one or more target cells, tissues, or organs of a subject, does not reasonably provide enablement for a method of delivering any sulfated polypeptide agent systematically to one or more target cells, tissues, or organs of a subject. Claim 2 is rejected because the specification, while being enabling for a method of reducing the toxicity of a mini-nucleosome core protein by systematically delivering a sulfated form of the mini-nucleosome core protein to a subject, does not reasonably provide enablement for a method of reducing the toxicity of any polypeptide agent by systematically delivering a sulfated form of the polypeptide agent to a subject. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.
“[T]o be enabling, the specification of a patent must teach those skilled in the art how to make and use the full scope of the claimed invention without ‘undue experimentation.’” Genentech Inc. v. Novo Nordisk 108 F.3d 1361, 1365, 42 USPQ2d 1001, 1004 (Fed. Cir. 1997); In re Wright 999 F.2d 1557, 1561, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993); See also Amgen Inc. v. Chugai Pharm. Co., 927 F.2d 1200, 1212, 18 USPQ2d 1016, 1026 (Fed. Cir. 1991); In re Fisher 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970). Further, in In re Wands 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988) the court stated:
Factors to be considered in determining whether a disclosure would require undue experimentation have been summarized by the board in Ex parte Forman [230 USPQ 546, 547 (BdPatAppInt 1986)]. They include (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredict-ability of the art, and (8) the breadth of the claims.
A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation. In re Wright, 999 F.2d 1557,1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993).
Nature of the Invention
The invention of claims 1 and 3 is drawn to a method of delivering a polypeptide agent to a cell, tissue, or organ of a subject by systematically administering a sulfated polypeptide agent. The invention of claim 2 is drawn to a method of reducing the toxicity of a polypeptide agent by systematically delivering a sulfated form of the polypeptide agent to a subject resulting in reduction of accumulation in liver and/or kidney.
Breadth of the Claims
The claims are broad. The polypeptide agent in general is not restricted such that the claims encompass any polypeptide. Claims 6 and 7 restrict to certain subclasses of polypeptides but still leave broad categories: antibodies, antibody fragments, enzymes, structural proteins, or viral vectors. Claim 10 limits to polypeptides where a non-sulfated version has been approved by the US FDA, which is still a broad genus.
The cells, tissues, or organs essentially encompass any possible structure in a subject. Later claims limit to muscle tissue while maintaining a broadly claimed polypeptide agent.
Claims 32 and 33 disclaim certain types of polypeptides while allowing for all other types to read upon the method. This still leaves a very broad genus of compounds.
State of the Prior Art
The art recognizes that sulfated polypeptides can serve as hormones in plants (see e.g. Kaulfmann and Sauter, J. Exp. Bot. 4267-4277, published 2019).
PEGylated mini-nucleosomes are utilized for nucleic acid delivery to cells per WO 2020/097235 A1. The ‘235 art does mention sulfation of mini-nucleosome core proteins as part of a list of amino acid modifications but does not explicitly show or discuss this modification as impacting delivery to cells, tissues, or organs (see e.g. [0047], claim 42).
Relative Skill of those in the Art
The relative skill of those in the art is high.
Predictability or Unpredictability of the Art
There is a general lack of predictability in the pharmaceutical art. In re Fisher, 427, F. 2d 833, 166, USPQ 18 (CCPA 1970).
Amount of Direction or Guidance Given
The specification alleges that sulfation of polypeptides, noting mini-nucleosomes as a particular example, as increasing nucleic acid compaction and allowing for delivery of associated nucleic acids to specific cells, tissues, or organs (see e.g. [0061]). The guidance on exemplary polypeptides mirrors the claims (see e.g. [0063]). Sulfation typically occurs at a tyrosine residue, although the specification does not indicate that this is the only point for sulfation to occur (see e.g. [0065]). The specification highlights mini-nucleosomes again as a particular target for sulfation and delivery into cells, tissues, or organs (see e.g. [0068]). Various targeting domains, stability domains, and oligomerization domains can be included (see e.g. [0070]-[0078]). Specific mini-nucleosome examples are offers in Table 1, encompassing SEQ ID NOs: 144-195 (see e.g. [0080]).
Presence/Absence of Working Examples
Example 1 concerns a comparison between sulfated and non-sulfated polypeptides in muscle delivery, where Agent 118 represents the elected SEQ ID NO: 196 and Agent 117 is a non-sulfated counterpart. Example 2 shows nucleic acid delivery via Agent 118 to skeletal, cardiac, and diaphragm muscle cells in a model of Duchenne Muscular Dystrophy (DMD). Example 3 shows use of specific promoter sequences to express a luciferase reporter gene in muscle cells. Example 4 shows expression of nucleic acids delivered by Agent 118 in tibialis anterior and gastrocnemius muscles of mice. Example 5 shows delivery of a dystrophin nucleic acid via Agent 118 in a mouse model of DMD, resulting in decreased creatine kinase levels indicating treatment of DMD. Example 6 shows expression of dystrophin in muscle after injection of a dystrophin nucleic acid complexed with Agent 118 in MDX mice.
Quantity of Experimentation Necessary
The onus is largely placed on the skilled artisan to conduct the experimentation covering the breadth of the claims. The specification reasonably can demonstrate mini-nucleosome core peptides can deliver nucleic acids to muscle cells and tissue. However, there is no reasonable extrapolation from that data to any sulfated polypeptide being specifically delivered to cells, tissues, or organs. For instance, there is no evidence that a well-known therapeutic peptide such as a GLP-1 agonist containing a sulfated tyrosine residue is specifically targeted to any cells, tissues, or organs. The breadth of a polypeptide agent as claimed is such that the skilled artisan is presented with an extremely broad genus to test, with no particular indication of particular cells, tissues, or organs to expect delivery. The skilled artisan must test through both broadly claimed polypeptides as well as broadly claimed cells, tissues, and organs. The onus is solely on the skilled artisan given the narrow focus of the disclosure, guidance, and examples in the instant application. Essentially, the skilled artisan is given a broad hypothesis that sulfated polypeptides lead to specific cell delivery and tasked to verify the thesis. This is also true for the method of reducing toxicity in claim 2, where the skilled artisan must verify that sulfation necessarily reduces toxicity and accumulation of any polypeptide agent in liver and/or kidney. Such experimentation is undue given the broad scope of the claims, lack of guidance, limited experiments, and lack of predictability in the art.
In view of the Wands factors as discussed above, it is the Examiner’s opinion that the claims are not fully enabled and one of skill in the art would have to engage in undue experimentation to practice the invention as claimed herein, without a reasonable assurance of success.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1, 3, 5, 7-9, 16, and 17 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 124, 125, and 127 of copending Application No. 19/570,020 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the ‘020 application claims an overlapping peptide.
The ‘020 application claims a sulfated polypeptide comprising SEQ ID NO: 388 (see e.g. claim 124). The ’020 application also claims a composition with this same peptide (see e.g. claim 125).
The ‘020 application does not claim a method of delivering polypeptide agents to target cells, tissues, or organs of a subject by systematically administering the sulfated polypeptide agent. However, the Federal Circuit has found that lack of an explicit claim to a method of use does not preclude a double patenting rejection if an identical use to an identical composition is disclosed in the reference patent:
A claim to a method of using a composition is not patentably distinct from an earlier claim to the identical composition in a patent disclosing the identical use (Sun Pharmaceutical. Industries, Ltd. v. Eli Lilly & Co., 611 F.3d 1381 (Fed. Cir. 2010)).
The ‘020 discloses that the sulfated polypeptide of SEQ ID NO: 388 was administered to a mouse and the reporter gene was expressed in neurons, indicating delivery to a target cell after systemic delivery while the non-sulfated form does not accumulate in those same cells (see e.g. [0144]-[0145]). This overlaps with claims 1 and 3.
With respect to claim 5, tyrosines are the relevant point for sulfation in SEQ ID NO: 388.
With respect to claim 7-9, SEQ ID NO: 388 is a mini-nucleosome.
With respect to claim 16, the expression of luciferase as compared to non-sulfated version indicates accumulation is increased as compared to the non-sulfated version.
With respect to claim 17, as noted above luciferase is utilized as a nucleic acid sequence encoding an expression product that is expressed in neurons.
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Conclusion
No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to ZACHARY J MIKNIS whose telephone number is (571)272-7008. The examiner can normally be reached Mon-Thurs 7-5.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melissa Fisher can be reached at (571) 270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/ZACHARY J MIKNIS/Patent Examiner, Art Unit 1658